Breakthrough PTSD treatment achieves 68% remission rate in clinical trial

Friday, October 23, 2026

Want headlines delivered to your inbox?
Subscribe to our free daily newsletter.

Search Headlines:

Match Type:BroadStrict



A newly FDA-cleared PTSD treatment uses personalized brain mapping and magnetic stimulation to target abnormal brain activity, with a clinical trial reporting a 52% reduction in symptoms and 68% remission. Researchers believe the technology could transform PTSD care and pave the way for more precise treatments for other mental health conditions. (via Science Daily)

Read the Full Story
This article will expire in 29 days.

In the News...

View All Recent News

Note: News headlines appearing on this site do not reflect the opinion of RxChat.com or its staff.